Cellulära interventioner och restitution av insulinproducerande celler vid typ 1 diabetes: ett riksomfattande program för utveckling av nya behandlingar
Tidsperiod: 2014-01-01 till 2017-12-31
Budget: 25 143 000 SEK
This work aims to find strategies to prevent beta-cell death and restore beta-cell mass in Type 1 diabetes (T1D) in the absence of chronic immune suppression, i.e. to provide curative treatment. This project plan specifically describes the translation of three of our intervention strategies to different patient groups with T1D. We have recently concluded a first study with mesenchymal stem cells (MSCs) in treatment of recently diagnosed patients with T1D, and observe preserved residual beta-cell function in treated patients. We now apply for a double-blinded phase II trial. If successful, this treatment will be tested also in high-risk individuals to prevent disease. Islet transplantation provides a mean to restore normoglycemia, but presently necessitate life-long immune suppression. We will investigate the possibility to use regulatory T-cells in order to eliminate the need of systemic immunosuppression after islet transplantation. Encapulation of islets to avoid immune attack is another possibility, but normally causes hypoxia-related cell death in the grafts. We will perform the first trial in humans with a specially designed oxygenated islet-containing macroencapsulation device. Successful application would open the possibility not only for transplantation to less strictly selected T1D patients, but also in the future for transplantation of xenogeneic or stem-cell derived insulin-producing cells thereby solving the limitation of donor organs.